Veracyte is continuing to aggressively build its cancer diagnostics business with an agreement to acquire HalioDx for €147m ($180m) in cash and up to €113m ($138m) in stock, the companies announced on 1 June.
Veracyte is a San Francisco-based genomics company focused on cancer diagnostics. HalioDx operates immuno-oncology laboratories in Richmond, VA, and Marseille, France, along with a manufacturing facility in Marseille that develops,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?